Main Long-Term Risks of Fosamax
Fosamax (alendronate), a bisphosphonate used to treat osteoporosis, carries risks that emerge or worsen after years of use, primarily affecting bone, jaw, and esophagus. The most documented long-term concern is atypical femoral fractures, which occur after 3+ years of therapy in rare cases (about 1 in 1,000 users per year after 5 years). These fractures happen with minimal trauma, often in the thigh bone subtrochanteric or diaphyseal region, due to suppressed bone remodeling leading to brittle, overly dense bone.[1][2]
Osteonecrosis of the jaw (ONJ), or "dead jaw," affects roughly 1 in 10,000 to 1 in 100,000 patients annually after prolonged use, especially in those with dental procedures, cancer, or poor oral health. Symptoms include jaw pain, swelling, and exposed bone.[1][3]
Esophageal issues like ulcers or strictures persist as risks with long-term dosing, particularly if not taken correctly (upright position with water).[2]
How Common Are Atypical Femur Fractures?
These fractures link directly to extended bisphosphonate suppression of osteoclasts, which normally renew bone. FDA data from 2009-2019 show incidence rises with duration: under 3 years, nearly zero; 3-7 years, 5 per 10,000 patient-years; over 8 years, up to 113 per 10,000.[4] A 2016 study of 477 cases found 81% had used bisphosphonates over 3 years.[1] Drug holidays (pausing after 3-5 years) reduce risk without major bone density loss.[2]
What About Osteonecrosis of the Jaw?
ONJ risk is low (0.001-0.1% yearly) but climbs with cumulative dose and invasiveness like tooth extractions. A 2020 meta-analysis of 190 studies reported odds ratios up to 10 times higher after 4+ years.[3] Oral surgeons now screen bisphosphonate users pre-procedure.
Other Long-Term Concerns Patients Report
- Atrial fibrillation: Some observational studies note a slight increase (1.3 relative risk) after 1+ years, though FDA deems evidence inconsistent.[2]
- Bone pain or delayed healing: Musculoskeletal pain can linger; non-healing fractures reported post-discontinuation.
- Hypocalcemia: Rare but serious in long-term users with vitamin D deficiency.
No strong links to cancer or cognitive issues, per current data.[1]
When Do Doctors Recommend Stopping Fosamax?
Guidelines from American Society for Bone and Mineral Research (2016, updated 2022) suggest reassessing after 3-5 years for low-risk patients or 5+ years for high-risk (e.g., prior fractures). Switch to denosumab or teriparatide if needed. Risk-benefit favors continuation in severe osteoporosis.[2][5]
How Do Risks Compare to Fracture Prevention Benefits?
Fosamax cuts vertebral fracture risk by 50% and hip fractures by 40-50% over 3-4 years.[1] Long-term absolute risks remain low (e.g., <1% for ONJ), but monitoring via DEXA scans and dental checks is standard. Alternatives like Prolia (denosumab) or Tymlos (abaloparatide) have different profiles—Prolia risks include more ONJ (0.04-0.2%).[2]
[1]: FDA Label - Fosamax (https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020560s051lbl.pdf)
[2]: American College of Physicians - Bisphosphonate Therapy (https://www.acpjournals.org/doi/10.7326/M19-0888)
[3]: Journal of Dental Research - ONJ Meta-Analysis (https://journals.sagepub.com/doi/10.1177/0022034520938851)
[4]: FDA Adverse Event Reporting System (FAERS) Summary
[5]: JBMR - Drug Holiday Guidelines (https://asbmr.onlinelibrary.wiley.com/doi/10.1002/jbmr.2898)